efaroxan
Sign in to saveEfaroxan is an α2-adrenergic receptor antagonist and antagonist of the imidazoline receptor.
Research
304 papers- Idazoxan and Efaroxan Potentiate the Endurance Performances and the Antioxidant Activity of Ephedrine in Rats.Medicina (Kaunas, Lithuania) · 2021
- Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy.Movement disorders : official journal of the Movement Disorder Society · 1998
- Efaroxan acts peripherally to block the antisecretory and gastroprotective effects of moxonidine in rats.The Journal of pharmacology and experimental therapeutics · 1995
- Characterization of a KATP channel-independent pathway involved in potentiation of insulin secretion by efaroxan.Diabetes · 2001
- Identification of the monomeric G-protein, Rhes, as an efaroxan-regulated protein in the pancreatic beta-cell.British journal of pharmacology · 2002
via PubMed
Wikidata facts
- Mass
- 216.126
Show 3 more facts
- Commons category
- Efaroxan
- canonical SMILES
- CCC1(CC2=CC=CC=C2O1)C3=NCCN3
- chemical formula
- C₁₃H₁₆N₂O
Sources (2)
via Wikidata · CC0
~1 min read
Article
4 sectionsContents
- Synthesis
- See also
- References
- External links
Efaroxan is an α2-adrenergic receptor antagonist and antagonist of the imidazoline receptor.
==Synthesis== thumb|center|500px|class=skin-invert-image|Synthesis (Cmp#13): Revised:
Connections
propranolol
Entity
atenolol
Entity
adrenergic receptor
Entity
labetalol
Entity
levobunolol
Entity
exaprolol
Entity
digital object identifier
Entity
chemical formula
Entity
epinephrine
Entity
dopamine
Entity
molar mass
Entity
Q180686
Entity
L-tyrosine
Entity
phenylalanine
Entity
norepinephrine
Entity
antidepressant
Entity
CAS Registry Number
Entity
PubChem
Entity
Anatomical Therapeutic Chemical Classification System
Entity
hydrogenation
Entity